Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells

Poly (ADP-ribose) polymerase inhibitor (PARPi) resistance is a new challenge for antitumor therapy. The purpose of this study was to investigate the reversal effects of chidamide on fluzoparib resistance, a PARPi, and its mechanism of action. A fluzoparib-resistant triple-negative breast cancer (TNB...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xinyang, Yuan, Xiang, Wang, Ziming, Li, Jing, Liu, Zhiwei, Wang, Yukun, Wei, Limin, Li, Yuanpei, Wang, Xinshuai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894594/
https://www.ncbi.nlm.nih.gov/pubmed/35251986
http://dx.doi.org/10.3389/fonc.2022.819714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894594/
https://www.ncbi.nlm.nih.gov/pubmed/35251986
http://dx.doi.org/10.3389/fonc.2022.819714

Ejemplares similares